Gordon Saxty did his Masters in Medicinal Chemistry at the University of Manchester (UMIST) where, as part of this degree, he also worked at Sanofi (formally RPR). He then went on to do a PhD in Synthetic Organic Chemistry at Imperial College, London under the supervision of Professor Donald Craig.
INVENTOR On OVER 40 PUBLISHED
Breakthrough Therapy Designation
He previously held the position of Associate Director, Medicinal Chemistry at Astex Pharmaceuticals in Cambridge, UK where he worked for over 12 years on Fragment Based Drug Discovery (FBDD) programmes. Several of these have progressed into clinical trials as potential new drugs to treat cancer. He is also an inventor on over 40 published patents and is an author on one of the most accessed Journal of Medicinal Chemistry articles from 2007, on FBDD of PKB/Akt inhibitors.
Industrialist of the Year 2013
Malcolm Campbell 2019
As an individual who has made a significant contribution to industry in the early stages of their career, he was awarded the Royal Society of Chemistry Young Industrialist of the Year Award 2013. One of those contributions was recognised by the U.S. Food and Drug Administration (FDA) and erdafitinib has been granted Breakthrough Therapy Designation for the treatment of urothelial cancer, and more recently with the Malcolm Campbell Award.
Subsequently, he worked at a Contract Research Organisation called Fidelta in Zagreb for 5 years. As the Head of Chemistry of over 50 chemists this work involved various therapeutic areas, macrocycles and bRo5, new technologies in an integrated drug discovery setting.